Pharmafile Logo
Pharmafocus logo
Advanced Search

ISA Pharmaceuticals highlights positive clinical data at ASCO

June 6, 2023
Research and Development ASCO, Cancer, HPV, ISA Pharmaceuticals, Oncology

Clinical stage biotechnology company ISA Pharmaceuticals has announced positive phase 1 data at the American Society of Clinical Oncology (ASCO) …

News

Bellerophon shares top-line data from phase 3 trial of INOpulse for fILD

June 6, 2023
Medical Communications Bellerophon Therapeutics, Cardiology, clinical trials, fibrotic interstitial lung disease

Bellerophon Therapeutics has announced top-line results from its phase 3 REBUILD trial evaluating the safety and efficacy of INOpulse for …

News

GSK receives FDA file acceptance for Jemperli plus chemotherapy for treating endometrial cancer

June 6, 2023
Research and Development GSK, Jemperli, Oncology, endometrial cancer, oncology

GSK has announced that the US Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for …

News

AstraZeneca’s phase 4 trial stopped early after reaching pre-specified criteria

June 5, 2023
Research and Development ANNEXA-I, Andexxa, AstraZeneca, Neurology, clinical trial

AstraZeneca has announced that its post-marketing phase 4 ANNEXA-I trial has been stopped early after reaching its pre-specified stopping criteria. …

News

Quanticate announces strategic partnership with KPS Life

June 5, 2023
Medical Communications KPS Life, Pharmacy, Quanticate, fsp

Global biometric clinical research group Quanticate has announced a strategic partnership with US-based provider of functional service provision (FSP) solutions …

News

Allogene Therapeutics shares updated ALLO-501/501A phase 1 data in large B-cell lymphoma at ASCO annual meeting

June 5, 2023
Research and Development Allogene, LBCL, Oncology, lymphoma, oncology

Allogene Therapeutics has shared updated data from the phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in patients with relapsed/refractory (r/r) large …

News

Report finds NHS may miss out on new drugs due to rising costs

June 5, 2023
Sales and Marketing LSE, LSHTM, NHS, Pharmacy, University of York, drug prices

Figures from a team at the University of York, the London School of Economics and Political Science (LSE) and the …

News

NICE approves first treatment for obstructive HCM for NHS use

June 2, 2023
Medical Communications Bristol-Myers Squibb, Cardiology, NHS, NICE, obstructive HCM

The National Institute for Health and Care Excellence (NICE) has announced that it has approved mavacamten (Camzyos) for the treatment …

News

NICE recommends Pfizer’s rimegepant for preventing episodic migraine attacks

June 2, 2023
Medical Communications NHS, NICE, Neurology, Pfizer, migraine

The National Institute for Health and Care Excellence (NICE) has announced that it has recommended an oral treatment for the …

News

BioInvent receives Investigational New Drug approval for monoclonal antibody BI-1910

June 2, 2023
Research and Development BioInvent, NSCLC, Oncology, monoclonal antibody

Swedish clinical stage biotech company BioInvent has announced that it has received Investigational New Drug (IND) approval for its monoclonal …

News
towfiqu-barbhuiya-hn2hqoalbck-unsplash_1

European Parliament shares goal to tackle antimicrobial resistance

June 2, 2023
Medical Communications EU, European Parliament, Microbiology, antimicrobial resistance

The European Parliament has shared its recommendations for a “coordinated EU response to health threats posed by antimicrobial resistance,” according …

News

FDA approves ANDA of 20mg generic Nitisinone capsules

June 1, 2023
Medical Communications Analog Pharma, Dipharma, FDA, Nitisinone, Rare Diseases

Analog Pharma and Dipharma have announced that the US Food and Drug Administration (FDA) has approved their 20mg nitisinone capsules, …

News

FDA approves Pfizer’s RSV vaccine for older adults

June 1, 2023
Research and Development FDA, Infections and infestations, Pfizer, RSV, Vaccine

Global pharmaceutical company Pfizer has announced that the US Food and Drug Administration (FDA) has approved its respiratory syncytial virus …

News

Sanofi announce positive phase 2 data for MS drug frexalimab

June 1, 2023
Research and Development Neurology, Sanofi, clinical trial, frexalimab, multiple sclerosis

French pharmaceutical and healthcare company Sanofi have announced positive trial data from its phase 2 clinical study into its relapsing …

News

Lonza to acquire Synaffix to strengthen ADC development

June 1, 2023
Medical Communications ADC, Lonza, Oncology, Synaffix, drug development

Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company …

News

Bristol Myers Squibb’s NDA accepted by FDA

May 31, 2023
Medical Communications FDA, NDA, NSCLC, Oncology, bristol myers squibb

Global pharmaceutical company Bristol Myers Squibb (BMS) has announced that its New Drug Application (NDA) has been accepted by the …

News

SNIPR Biome reports positive findings for first-in-human, CRISPR-based microbial gene therapy

May 31, 2023
Research and Development Infections and infestations, SNIPR Biome, clinical trial, crispr, gene therapy

Danish CRISPR-based microbial gene therapy company SNIPR Biome have announced positive interim data from its phase 1 clinical trial with …

News

Pharmanovia and Stealth BioTherapeutics enter new licensing agreement for novel Barth syndrome treatment

May 31, 2023
Sales and Marketing Barth syndrome, Cardiology, Pharmanovia, Stealth BioTherapeutics, licensing agreement

Pharmanovia and Stealth BioTherapeutics have announced that they have entered into a new licensing agreement for the marketing and further …

News

Merck invests €35m in biosafety testing in Scotland

May 31, 2023
Manufacturing and Production Merck, biosafety, drug development, testing

Merck has announced that it has invested €35m in biosafety testing at its sites in Glasgow and Stirling, both Scotland. …

News

Pulse Medical receives FDA BDD for its μFR system

May 30, 2023
Medical Communications BDD, Cardiology, FDA, Pulse Medical

Shanghai, China-based Pulse Medical Technology has announced that its 4th generation μFR system has received Breakthrough Device Designation (BDD) from …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026